|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, immunohistochemical staining demonstrated that high MUC20 expression correlated with poor progression-free survival and high local recurrence rate of PDAC patients (n = 61).
|
29993037 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer.
|
30784116 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mucin (MUC) 20 has recently been implicated to play a role in human carcinogenesis.
|
26616226 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
|
Cystic Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regions on chr3q29 (MUC4/MUC20; P=3.3 × 10(-11)), chr5p15.3 (SLC9A3; P=6.8 × 10(-12)), chr6p21.3 (HLA Class II; P=1.2 × 10(-8)) and chrXq22-q23 (AGTR2/SLC6A14; P=1.8 × 10(-9)) contain genes of high biological relevance to CF pathophysiology.
|
26417704 |
2015 |
|
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
|
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
|
Epithelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Previously, it has been reported that MUC13 and MUC20 were prognostic molecular biomarkers of some epithelial tumors, but few has studied the relations between MUC13 or MUC20 expression and the prognosis of patients with esophageal squamous cell carcinoma (ESCC).
|
26323930 |
2015 |
|
IGA Glomerulonephritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These characteristics suggest that the production of MUC20 is correlated with development and progression of IgAN and other renal injuries.
|
14565953 |
2004 |
|
IGA Glomerulonephritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of the alleles and genotypes of MUC20 VNTR polymorphisms did not differ between patients with IgAN and healthy controls.
|
16508246 |
2006 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
|
Laryngitis
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux.
|
18834073 |
2008 |
|
Lupus Nephritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mouse MUC20 mRNA was expressed in the epithelial cells of proximal tubules, and the expression increased dramatically with the progression of lupus nephritis in the kidney of MRL/MpJ-lpr/lpr mice.
|
14565953 |
2004 |
|
Malignant neoplasm of endometrium
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
|
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis using the Gene Expression Omnibus public microarray database indicated higher DUSP28, MUC1, MUC4, MUC5B, MUC16 and MUC20 messenger RNA (mRNA) levels in pancreatic cancers compared with normal pancreas tissues.
|
27230679 |
2016 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that MUC20 enhances aggressive behaviors of EOC cells by activating integrin β1 signaling and provide novel insights into the role of MUC20 in ovarian cancer metastasis.
|
26616226 |
2016 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MUC20 expression was assessed in tissue microarray and tumor specimens of EOC patients by immunohistochemistry.
|
26616226 |
2016 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
|
29993037 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 high expression was associated with age, histology, positive peritoneal cytology, advanced stage, and lymph node metastasis (P < 0.05).
|
30784116 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of MUC13 and MUC20 in ESCC mainly occurred in the cytoplasm.
|
26323930 |
2015 |